CAMBRIDGE, Mass. — Cognito Therapeutics has closed an oversubscribed $105 million Series C financing round as the Cambridge-based neurotechnology company moves toward pivotal clinical data, regulatory submission, and a planned commercial launch of its Alzheimer’s therapy platform in 2027.
The financing round was led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from new investors including New Vintage, Apollo Health Ventures and Benvolio Group, among others.
Company officials said the new funding will support ongoing clinical development of its Spectris therapeutic platform, preparation for regulatory submission, and commercialization planning. The capital will also help expand the platform’s research into additional neurodegenerative diseases through a network of brain health collaboratories, beginning with the WVU Rockefeller Neuroscience Institute.
“With this financing, we are entering a pivotal moment for our company, and for the patients and families waiting for new options in Alzheimer’s disease,” said Christian Howell, Chief Executive Officer, Cognito Therapeutics. “Spectris has the potential to become the world’s first physician-prescribed, at-home neuroprotective therapy for patients diagnosed with Alzheimer’s, designed to preserve cognition and daily function. This funding allows us to make this therapy accessible to those who need it most.”
Spectris is an investigational, physician-prescribed therapeutic platform designed for at-home use. The system uses non-invasive visual and auditory stimulation intended to evoke coordinated neural activity across interconnected brain networks. Researchers are studying whether the approach can help preserve cognition, daily functioning, and brain structure in people diagnosed with Alzheimer’s disease.
“Advancing precision medicine for Alzheimer’s disease by expanding the range of treatment options available to patients is critically important,” said Howard Fillit, M.D., Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). “Novel technologies like Cognito’s, which are non-invasive and accessible, will be an important part of the broad and comprehensive treatment approach that will define the future of Alzheimer’s care. Ultimately, we will be able to combine therapeutics, lifestyle interventions, and devices to treat each patient based on their individual risk profiles.”
“Cognito represents a rare convergence of rigorous neuroscience research, clinical validation, elegant engineering, and a deep understanding of patient needs,” said Gerald Chan, Sc.D., Founder of Morningside Ventures and Chairman of the Board at Cognito. “Spectris has the potential to redefine how a broad category of neurodegenerative diseases are treated, by moving therapy into the home, reducing burden on patients and caregivers, and scaling impact globally. We are proud to continue supporting Cognito as it advances toward regulatory submission and broader clinical impact.”
Cognito said its HOPE pivotal study (NCT05637801) is fully enrolled, with top-line data expected later this year. The Spectris system remains an investigational device and has not yet been approved by the U.S. Food and Drug Administration.
